Literature DB >> 24969924

Neurosurgical oncology: advances in operative technologies and adjuncts.

Randy S D'Amico1, Benjamin C Kennedy, Jeffrey N Bruce.   

Abstract

Modern glioma surgery has evolved around the central tenet of safely maximizing resection. Recent surgical adjuncts have focused on increasing the maximum extent of resection while minimizing risk to functional brain. Technologies such as cortical and subcortical stimulation mapping, intraoperative magnetic resonance imaging, functional neuronavigation, navigable intraoperative ultrasound, neuroendoscopy, and fluorescence-guided resection have been developed to augment the identification of tumor while preserving brain anatomy and function. However, whether these technologies offer additional long-term benefits to glioma patients remains to be determined. Here we review advances over the past decade in operative technologies that have offered the most promising benefits for glioblastoma patients.

Entities:  

Mesh:

Year:  2014        PMID: 24969924     DOI: 10.1007/s11060-014-1493-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  167 in total

1.  Sequential visualization of brain and fiber tract deformation during intracranial surgery with three-dimensional ultrasound: an approach to evaluate the effect of brain shift.

Authors:  Volker A Coenen; Timo Krings; Jürgen Weidemann; Franz-Josef Hans; Peter Reinacher; Joachim M Gilsbach; Veit Rohde
Journal:  Neurosurgery       Date:  2005-01       Impact factor: 4.654

2.  Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.

Authors:  Sandeep Kunwar; Susan M Chang; Michael D Prados; Mitchel S Berger; John H Sampson; David Croteau; Jeffrey W Sherman; Amy Y Grahn; Vince S Shu; Jeanne L Dul; Syed R Husain; Bharat H Joshi; Christoph Pedain; Raj K Puri
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

3.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

4.  Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.

Authors:  Matthew J McGirt; Alan T Villavicencio; Ketan R Bulsara; Henry S Friedman; Allan H Friedman
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

5.  Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Authors:  John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

6.  Motor and language DTI Fiber Tracking combined with intraoperative subcortical mapping for surgical removal of gliomas.

Authors:  Lorenzo Bello; Anna Gambini; Antonella Castellano; Giorgio Carrabba; Francesco Acerbi; Enrica Fava; Carlo Giussani; Marcello Cadioli; Valeria Blasi; Alessandra Casarotti; Costanza Papagno; Arun K Gupta; Sergio Gaini; Giuseppe Scotti; Andrea Falini
Journal:  Neuroimage       Date:  2007-08-29       Impact factor: 6.556

7.  5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature.

Authors:  Alessandro Della Puppa; Serena De Pellegrin; Elena d'Avella; Giorgio Gioffrè; Marta Rossetto; Alessandra Gerardi; Giuseppe Lombardi; Renzo Manara; Marina Munari; Marina Saladini; Renato Scienza
Journal:  Acta Neurochir (Wien)       Date:  2013-03-07       Impact factor: 2.216

8.  Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere.

Authors:  Hugues Duffau; S T Peggy Gatignol; Emmanuel Mandonnet; Laurent Capelle; Luc Taillandier
Journal:  J Neurosurg       Date:  2008-09       Impact factor: 5.115

9.  Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients.

Authors:  G Evren Keles; David A Lundin; Kathleen R Lamborn; Edward F Chang; George Ojemann; Mitchel S Berger
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

10.  Objective assessment of utility of intraoperative ultrasound in resection of central nervous system tumors: A cost-effective tool for intraoperative navigation in neurosurgery.

Authors:  Aliasgar Moiyadi; Prakash Shetty
Journal:  J Neurosci Rural Pract       Date:  2011-01
View more
  17 in total

1.  Spectral and lifetime domain measurements of rat brain tumors.

Authors:  D Abi Haidar; B Leh; M Zanello; R Siebert
Journal:  Biomed Opt Express       Date:  2015-03-11       Impact factor: 3.732

Review 2.  Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Authors:  Sonya E L Craig; James Wright; Andrew E Sloan; Susann M Brady-Kalnay
Journal:  World Neurosurg       Date:  2016-02-23       Impact factor: 2.104

3.  Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention.

Authors:  Brian W Pogue; Keith D Paulsen; Kimberley S Samkoe; Jonathan T Elliott; Tayyaba Hasan; Theresa V Strong; Daniel R Draney; Joachim Feldwisch
Journal:  Med Phys       Date:  2016-06       Impact factor: 4.071

4.  On the use of fluorescein-based contrast agents as analogs to MRI-gadolinium agents for imaging brain tumors.

Authors:  Scott C Davis; Margaret R Folaron; Rendall R Strawbridge; Caroline Filan; Kimberley S Samkoe; David W Roberts
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-03-07

Review 5.  Polymeric drug delivery for the treatment of glioblastoma.

Authors:  Scott D Wait; Roshan S Prabhu; Stuart H Burri; Tyler G Atkins; Anthony L Asher
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

Review 6.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

Review 7.  Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

Authors:  Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-05-14       Impact factor: 12.300

Review 8.  The value of extent of resection of glioblastomas: clinical evidence and current approach.

Authors:  Joao Paulo Almeida; Kaisorn L Chaichana; Jordina Rincon-Torroella; Alfredo Quinones-Hinojosa
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

Review 9.  Convection-enhanced drug delivery for glioblastoma: a review.

Authors:  Randy S D'Amico; Manish K Aghi; Michael A Vogelbaum; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

10.  Post Mortem Validation of MRI-Identified Veins on the Surface of the Cerebral Cortex as Potential Landmarks for Neurosurgery.

Authors:  Günther Grabner; Thomas Haider; Mark Glassner; Alexander Rauscher; Hannes Traxler; Siegfried Trattnig; Simon D Robinson
Journal:  Front Neurosci       Date:  2017-06-21       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.